Scarica l'app Stockscreener
4.37
0.68%
-0.03
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio stock hits 52-week low at $4.52 amid market challenges - Investing.com Australia
When (ANVS) Moves Investors should Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Eyes Clear Path Forward For Buntanetap - Barchart
Annovis Bio, Inc. (NYSE:ANVS) Short Interest Update - MarketBeat
Royal Bank of Canada (RY-N) QuotePress Release - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Annovis Bio (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Investor Webcast - Barchart
Annovis Bio, Inc. Appoints William Fricker to Serve as Chief Financial Officer on an Interim Basis - Marketscreener.com
Annovis Bio Announces Investor Webcast to Share Key Updates - MSN
Annovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials - TipRanks
Form 424B5 Annovis Bio, Inc. - StreetInsider.com
Annovis Bio appoints interim CFO By Investing.com - Investing.com Nigeria
Annovis Bio appoints interim CFO - Investing.com
Annovis Bio Appoints William Fricker as Interim CFO - TipRanks
(ANVS) On The My Stocks Page - Stock Traders Daily
Annovis Bio (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace - Barchart
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate - Simply Wall St
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - GlobeNewswire
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s - The Bakersfield Californian
Annovis Bio (NYSE: ANVS) to Present Recent Achievements, Strategic Outlook During Investor Webcast - Barchart
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace - PR Newswire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Down Syndrome Market expected to rise | Companies- Eisai, AC Immune, Elixirgen Therapeutics, Aphios Therapeutics, Avanti Biosciences, Annovis Bio, AelisFarma, Kinopharma, NeuroNascent, Pharmasum Thera - Barchart
Annovis Bio (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates - Barchart
Annovis to Host Year-End Investor Webcast on December 11, 2024 - The Manila Times
Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) Target Price at $32.17 - MarketBeat
Annovis Bio (NYSE: ANVS) Paving The Way For NDA Submission - Barchart
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN
When the Price of (ANVS) Talks, People Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart
Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat
Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - citybiz
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):